Publications scientifiques sur les diagnostics non invasifs BioPredictive
Études évaluées par les pairs validant les diagnostics sanguins BioPredictive pour les maladies du foie — des cohortes pionnières aux méta-analyses à long terme.
108/435
Résultats pour
“applicability”
-
Applicability and variability of liver stiffness measurements according to probe position.
### Aim To investigate the liver stiffness measurement (LSM) applicability and variability with…
-
Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard.
…The aim was to assess the applicability and performances of SWE for…
-
FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate.
…after taking into account the applicability rates. ### Methods One thousand two hundred…
-
Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.
…The aims were to compare several criteria of applicability, and to assess…
-
Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age.
…To assess the applicability rate and to reduce the risk of false…
-
Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C.
…EFT took into account the applicability of both tests, included two algorithms…
-
Hepatitis B: are non-invasive markers of liver fibrosis reliable? Review
…Advantages of serum biomarkers include their high applicability (>95%) and good reproducibility…
-
Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease.
-
Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Meta Analysis
### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…
-
Toward non-invasive assessment strategies in autoimmune hepatitis.
In this article, we comment on the article by Peta _et al…
-
Letter: FibroTest for staging fibrosis in non-alcoholic fatty liver disease - authors' reply.
-
Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers.
### Background Assessing liver fibrosis is traditionally performed by biopsy, an imperfect gold…
-
Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C.
-
The use of enzyme results for liver fibrosis evaluation neccessitates standardization.
-
Biopsy as well as FibroTest/Fibrosure is suboptimal for discriminating intermediate fibrosis stages in patients with chronic hepatitis B.
-
Screening studies of transient elastography and FibroTest in the general population.
-
Noninvasive diagnosis in alcohol-related liver disease.
…several limitations, including invasiveness, low applicability, sampling variability, and cost. ### Main Text…
-
Clinical applicability of non-invasive markers for liver fibrosis in chronic hepatitis C (Letter)
-
FibroTest (FT) has similar accuracy for cirrhosis in 'intention-to-diagnose' which is superior to transient elastography (TE) in chronic hepatitis B.
-
Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt.
In Egypt, as elsewhere, liver biopsy (LB) remains the gold standard to…
-
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication
-
Noninvasive evaluation of NAFLD. Review
…main limitation is its reduced applicability in patients with NAFLD, which is…
-
Screening studies of transient elastography and FibroTest in the general population - Authors' reply.
-
Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).
### Background & Aims FibroTest™ (FT) and Transient Elastography (TE) have been validated as…
-
Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis. Key publication
### Background No prospective diagnostic studies have directly compared widespread non-invasive liver…
-
Noninvasive Assessment of Liver Fibrosis.
### Background The prognosis and management of chronic liver diseases greatly depend on…
-
Biomarkers of liver fibrosis. Review
Liver biopsy, due to its limitations and risks, is an imperfect gold…
-
Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study.
…of patients to assess its applicability in patients with HCV and steatosis.
-
Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study.
…excellent diagnostic performance, demonstrating its applicability for routine screening in diabetology. The…
-
Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication Review
This review summarizes the methodological aspects of the interpretation of non-invasive…
-
Impact of steatosis and inflammation definitions on the performance of NASH tests.
### Background And Aim One of the unmet needs in subjects with metabolic…
-
Prospective evaluation of FibroTest®, FibroMeter®, and HepaScore® for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C.
### Background & Aims Fibrosis blood tests have been validated in chronic hepatitis C…
-
Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis.
### Background & Aims There is controversy about the performance of noninvasive tests such…
-
Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation.
### Background The area under the receiver operating characteristic (ROC) curve is widely…
-
Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.
### Background Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement for…
-
FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. Meta Analysis
### Objectives Extent of liver fibrosis is one of the most important factors…
-
Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).
### Background FibroTest and elastography have been validated as biomarkers of liver fibrosis…
-
ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. Meta Analysis
### Background ActiTest (AT) is a biomarker of liver necro-inflammatory histological activity…
-
Prognostic value of liver fibrosis biomarkers: a meta-analysis.
### Aims And Methods Several serum biomarkers such as FibroTest, aspartate transaminase-platelet…
-
Spleen stiffness measurement by transient elastography to diagnose portal hypertension in children.
### Background The development of esophageal varices is a late complication of chronic…
-
Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.
### Aim To assess the performance of several non-invasive markers and of…
-
Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".
### Background The aspartate aminotransferase platelet ratio index (APRI) is a validated, non…
-
Including osteoprotegerin and collagen IV in a score-based blood test for liver fibrosis increases diagnostic accuracy.
### Background Noninvasive methods for liver fibrosis evaluation in chronic liver diseases have…
-
Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. Review
### Background Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum of…
-
Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. Key publication
### Background Although the FibroTest has been validated as a biomarker to determine…
-
Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease.
### Background And Aims The PGAA index was one of the first composite…
-
Diagnostic value of FibroTest with normal serum aminotransferases.
-
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. Review
Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C…
-
Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).
### Background & Aims The first aim was to extend the validation of FibroTest…
-
Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.
### Introduction A prognostic model to predict liver severity in people with metabolic…
-
The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication
### Background Serum biomarkers of steatosis such as the SteatoTest are recommended for…
-
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Key publication
### Background Blood tests of liver injury are less well validated in non…
-
Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience.
### Background The Fibrotest-Actitest is a six-parameter scoring system that allows…
-
Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Review
…non-invasive tests, reviewing their diagnostic performance and applicability to patient care.
-
A simple biological index for detection of alcoholic liver disease in drinkers.
To make liver biopsy unnecessary in certain cases, PGA (P, prothrombin time…
-
Non-invasive markers for hepatic fibrosis. Review
With great advancements in the therapeutic modalities used for the treatment of…
-
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes. Key publication
### Background One of the unmet needs in patients with type 2 diabetes…
-
Current Possibilities to Assess the Degree of Liver Fibrosis in Patients with Haemophilia Infected with HCV--Review. Review
Haemophilia is an entity, wherein the HCV infection rate is greater than…
-
Concordance of non-invasive serology-based scoring indices and transient elastography for liver fibrosis and cirrhosis in chronic hepatitis C.
Aim To assess concordance of eight frequently used serology-based scoring indices…
-
Non-invasive Investigations for the Diagnosis of Fontan-Associated Liver Disease in Pediatric and Adult Fontan Patients.
Fontan-associated liver disease (FALD) is a serious complication related to the…
-
Liver fibrosis in young Egyptian beta-thalassemia major patients: relation to hepatitis C virus and compliance with chelation.
### Background The main causes of liver fibrosis in transfusion-dependent thalassemia major…
-
Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index.
As an alternative to liver biopsy, an index of five biochemical markers…
-
Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C.
### Background & Aims Non-invasive assessment of liver fibrosis is a challenging area…
-
The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis.
### Background And Aims Blood tests and liver stiffness evaluation (LSE) by ultrasonographic…
-
Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B.
### Background And Aims Liver stiffness measurement (LSM) and FibroTest (FT) are frequently…
-
Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.
### Background Aims Liver biopsy is the gold standard for assessing hepatitis B…
-
Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers.
### Background Low-dose oral methotrexate (MTX) is an effective immunosuppressive therapy for…
-
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. Meta Analysis
### Background Liver biopsy is considered as the gold standard for assessing non…
-
Intestinal failure-associated liver disease in patients with short bowel syndrome: Evaluation by transient elastography.
### Objective Patients with short bowel syndrome (SBS) receiving long-term parenteral nutrition…
-
Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B.
### Background And Aims Diagnostic values of FibroTest (FT) for hepatic fibrosis have…
-
Prospective noninvasive analysis of hepatic fibrosis in patients with Crohn's disease: correlation of transient elastography and laboratory-based markers.
### Background And Aims Hepatobiliary disorders, associated either with extraintestinal manifestations or with…
-
Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study.
### Background & Aims Blood tests and transient elastography (Fibroscan™) have been developed as…
-
Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.
### Background And Aims Apolipoprotein A1 (A1) and haptoglobin (HP) serum levels are…
-
Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.
### Background & Aims Liver fibrosis stage is traditionally assessed with biopsy, an imperfect…
-
A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Key publication
### Background FibroTest, a noninvasive method of measuring biomarkers of liver fibrosis, is…
-
Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.
### Background/Aims According to guidelines, the histological diagnosis of severe alcoholic steatohepatitis…
-
Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.
### Background & Aims Time-dependent statistics have been used to assess liver fibrosis…
-
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.
### Background & Aims Chronic hepatitis C is both a virologic and fibrotic disease…
-
Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study--ANRS HC02.
### Background/Aims To compare non-invasive biological liver fibrosis scores, as alternatives…
-
Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. Key publication
### Background One of the unmet needs in patients with metabolic risks is…
-
Personalized management of cirrhosis by non-invasive tests of liver fibrosis. Review
Owing to the high prevalence of various chronic liver diseases, cirrhosis is…
-
The non-invasive assessment of hepatic fibrosis. Review
Hepatic disease accounts for approximately 2 million deaths/year worldwide. Liver fibrosis…
-
The effectiveness of noninvasive biomarkers to predict hepatitis B-related significant fibrosis and cirrhosis: a systematic review and meta-analysis of diagnostic test accuracy. Meta Analysis
Noninvasive biomarkers have been developed to predict hepatitis B virus (HBV)-related…
-
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
### Background In cardiometabolic disorders, non-alcoholic fatty liver disease is frequent and…
-
LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Key publication
### Background No blood test has been shown to be effective in the…
-
Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery.
### Background There is a clear need for better biomarkers of drug-induced…
-
Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. Key publication
### Objective There is a controversy about the performance of blood tests for…
-
Assessment of liver fibrosis: noninvasive means.
Liver biopsy, owing to its limitations and risks, is an imperfect gold…
-
Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease.
### Background African Americans have lower reported likelihood of hepatitis C virus-related…
-
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. Key publication
### Background & Aims The Liver Cancer Risk test algorithm (LCR1-LCR2) is a…
-
Noninvasive Assessment of Liver Fibrosis. Key publication Review
-
External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B. Key publication
### Background And Aims The liver cancer risk test (LCR1-LCR2) is a…
-
Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Key publication
**Background/Objectives:** Bariatric surgery (BS), drugs approved for type-2-diabetes (T2D…
-
An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.
**Background:** The current definition of metabolic dysfunction-associated steatotic liver disease (MASLD…
-
Non-invasive diagnosis and follow-up of portal hypertension.
Compensated advanced chronic liver disease (cACLD) describes the spectrum of advanced fibrosis…
-
Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review
Even though alcohol-related liver disease (ALD) is a major cause of…
-
FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication Meta Analysis
FibroTest (FT) is a biomarker of liver fibrosis initially validated in patients…
-
Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. Review
The limitations of liver biopsy (invasive procedure, sampling errors, inter-observer variability…
-
Acoustic Radiation Force Impulse Imaging for Diagnosis and Monitoring of Liver Fibrosis in Patients with Hepatitis C: A Review of Diagnostic Accuracy, Clinical Effectiveness, Cost-Effectiveness, and Guidelines Review
Acoustic Radiation Force Imaging (ARFI) is an emerging non-invasive procedure that…
-
Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication
### Background Since 1920, a decrease in serum cholesterol has been identified as…
-
Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.
-
Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis. Review
### Background Liver fibrosis is a sign of advanced liver disease and is…
-
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.
-
EASL clinical practical guidelines: management of alcoholic liver disease.
-
Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. Key publication
In patients with non-alcoholic fatty liver disease (NAFLD) with or without…
-
Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection Key publication
These are the first guidelines dealing with hepatitis C treatment produced by…
-
Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
### Background Excessive alcohol consumption may lead to the development of alcohol-related…
-
Prise en charge des personnes infectées par les virus de l’hépatite B ou de l’hépatite C — Rapport de recommandations 2014 Key publication
Affichage de la liste complète des résultats. La page est rendue côté serveur et non paginée.